Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
•To compare MK-5172A to SOF/PR in the treatment of HCV, as assessed by the proportion of subjects achieving SVR12 (Sustained Virologic Response 12 weeks after the end of all study therapy), defined as HCV RNA < LLOQ (either TD[u] or TND) 12 weeks after the end of all study therapy. •To evaluate the safety and tolerability of MK-5172A as compared to SOF/PR.
Inclusion criteria
- Hepatitis C